Laura Panjwani

Shaji Kumar, MD, discusses the roles that the recently released updated consensus criteria by the International Myeloma Working Group and MRD testing will play going forward in multiple myeloma.

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in the field of sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.

Katherine Thornton, MD, discusses the use of trabectedin and eribulin both within and outside of their approved indications for soft tissue sarcoma.

Researchers have created a new classification system for oropharyngeal cancer that is adjusted for the improved prognosis of patients with HPV-positive disease.

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

Maria-Victoria Mateos, MD, PhD, provides insight on a subanalysis of the TOURMALINE-MM1 trial, the impact of ixazomib's (Ninlaro's) approval, and the future of triplet combinations in the treatment multiple myeloma.

Richard J. Bold, MD, discusses the reasoning to break gastroesophageal junction cancers into multiple subgroups and why it is important for treatment and surgical decisions.

Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.

David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Hope S. Rugo, MD, discusses the recent findings with MYL-1401O and the role of biosimilars in patients with HER2-positive breast cancer.

Chau T. Dang, MD, discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

Denise Reinke, MS, NP, discusses the Sarcoma Alliance for Research through Collaboration, as well as the challenges and up-and-coming advancements in sarcoma.

Treatment with pembrolizumab (Keytruda) led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non–small cell lung cancer, although they are not commonly considered while doing mutation testing.

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Charlie Gourley, PhD, MBChB, discusses the potential use of olaparib (Lynparza) as a maintenance therapy for patients with ovarian cancer.

Andrzej Jakubowiak, MD, discusses the impact of a recent cross-study comparison analysis and the continued role of autologous stem cell transplantation in treatment of patients with multiple myeloma.

Cynthia Ma, MD, provides insight on the potential of glembatumumab vedotin (CDX-011) and immunotherapies on the horizon in the field of triple-negative breast cancer.